<DOC>
	<DOCNO>NCT02737228</DOCNO>
	<brief_summary>&lt; Part I - Phase I trial &gt; The phase I clinical trial identify MTD ( Maximum Tolerated Dose ) DLT ( Dose Limiting Toxicity ) CG200745 PPA combination use Gemcitabine Erlotinib . Initial dose CG200745 PPA 187.5 mg/m^2 , extend 250 mg/m^2 , 312.5 mg/m^2 reduce 125 mg/m^2 base result cohort 3 subject per dose level . Based 3+3 dose escalation study design , Gemcitabine Erlotinib administer fixed dos , whereas CG200745 PPA administer four different cohort accord dose level . Each cohort consist 3 6 subject . &lt; Part II - Phase II trial &gt; In phase II clinical trial , subject administer dose identify recommend dose base result Phase I study . The whole one cycle consist 28 day , phase I . The entire treatment period 6 cycle tumor assessment evaluate every 2 cycle .</brief_summary>
	<brief_title>Study CG200745 PPA Combination With Gemcitabine Erlotinib Advanced Pancreatic Cancer</brief_title>
	<detailed_description>&lt; Part I - Phase I trial &gt; The phase I clinical trial identify MTD DLT CG200745 PPA combination use Gemcitabine Erlotinib . Initial dose CG200745 PPA 187.5 mg/m^2 , extend 250 mg/m^2 , 312.5 mg/m^2 reduce 125 mg/m^2 base result cohort 3 subject per dose level . Based 3+3 dose escalation study design , Gemcitabine Erlotinib administer fixed dos , whereas CG200745 PPA administer four different cohort accord dose level . Each cohort consist 3 6 subject . - Dose level 0 : CG200745 PPA 125 mg/m^2 pul Gemcitabine 1000 mg/m^2 ) Erlotinib 100 mg - Dose level 1 : CG200745 PPA 187.5 mg/m^2 pul Gemcitabine 1000 mg/m^2 ) Erlotinib 100 mg - Dose level 2 : CG200745 PPA 250 mg/m^2 pul Gemcitabine 1000 mg/m^2 ) Erlotinib 100 mg - Dose level 3 : CG200745 PPA 312.5 mg/m^2 pul Gemcitabine 1000 mg/m^2 ) Erlotinib 100 mg &lt; Part II - Phase II trial &gt; In phase II clinical trial , subject administer dose identify recommend dose base result Phase I study . The whole one cycle consist 28 day , phase I . The entire treatment period 6 cycle tumor assessment evaluate every 2 cycle .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Ages : ≥ 20 ≤ 75 year Subjects join voluntarily participation study , sign consent form willing comply clinical trial procedure Subjects diagnose unresectable , locally advanced , metastatic , histologically cytologically confirm pancreatic adenocarcinoma ECOG ( Eastern Cooperative Oncology Group ) performance status : 02 Estimated life expectancy time enrollment 3 month Adequate hematological , renal hepatic function Absolute neutrophil count ( ANC ) ≥ 1500/mm3 , hemoglobin ≥ 9.0 g/dl ( eligible hemoglobin lab value adjust blood transfusion ) , platelet ≥ 100,000/mm3 Within normal range serum creatinine creatinine clearance rate ( CCr ) ≥ 60 ml/min ( use CockcroftGault equation ) Subjects abnormal serum electrolyte value ( include calcium , magnesium , phosphorous potassium ) . However , supplementation therapy allow normalization serum electrolytes . ※ Normal reference range Calcium : 8.3~10.5 mg/dl , Magnesium : 1.58~3.0 mg/dl , Phosphorous : 2.4~4.5 mg/dl , Potassium : 3.3~5.5 mmol/L Serum bilirubin &lt; 2 x Upper Limit Normal ( ULN ) , Aspartate Aminotransferase ( AST ) /Alanine Aminotransferase ( ALT ) &lt; 2.5 x ULN , Alkaline phosphatase ( ALP ) &lt; 5 x ULN ( If liver metastasis , AST/ALT &lt; 5 x ULN ) Prothrombin Time ( PT ) Partial thromboplastin time ( PTT ) ≤ 1.5 x ULN ( except use anticoagulant , case , PT/PTT stabilization 2 week confirm ) No prior chemotherapy , radiation biologics Subject experience major surgery within 2 week prior screen visit Subject evidence uncontrolled brain metastasis ( except patient radiologically neurologically stable brain metastasis without corticosteroid therapy least two week ) Subject administer oral drug , difficulty absorb study drug due history major gastrointestinal surgery pathological finding . Subjects treat antibiotic within last seven day due active bacterial infection prior enrollment . ( Topical antibiotic therapy exclude ) Subjects experienced malignancy within past 5 year , except basal cell skin cancer , situ cervical cancer , papillary thyroid tumor . Pregnancy Lactating Fertile subject agree effective contraception study period 3 month completion study . The following case exception : irreversible surgical sterility hysterectomy , bilateral oophorectomy bilateral salpingectomy , menopausal woman 50 year old menstruation least 12 month without hormonal therapy . Tubal ligation regard effective contraception Subject take anticancer chemotherapy due systemic disease ( ex . chronic renal failure ) Subjects treated investigational drug within 4 week prior screen visit History hypersensitivity study drug Subject HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>